The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy
Abstract
BACKGROUND.: The mammalian target of rapamycin (mTOR) pathway is up‐regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC). METHODS.: Immunohistochemical analysis using antibodies against pAkt, PTEN, p27, and pS6 was performed on a tissue microarray constructed from paraffin‐embedded specimens from 375 patients treated by nephrectomy for RCC. The expression was associated with pathological parameters and survival. RESULTS.: The mTOR pathway was more significantly altered in clear‐cell RCC, high‐grade tumors, and tumors with poor prognostic features. PS6 and PTEN showed the strongest associations with pathological parameters. Survival tree analysis regarding expression of cytoplasmic pAkt, nuclear pAkt, PTEN, cytoplasmic p27, and pS6 identified staining percentages of 40%, 10%, 75%, 7%, and 70%, respectively, as ideal cutoff values for stratification, with corresponding P‐values of .03, .001, .02, .005, and <.0001, respectively. Interestingly, high nuclear pAkt expression was associated with a favorable prognosis, whereas high cytoplasmic pAkt expression was associated with a poor prognosis. In multivariate Cox regression analysis, ECOG PS, T classification, N classification, M classification, cytoplasmic Akt, nuclear pAkt, PTEN, and pS6 were independent prognostic factors of DSS. CONCLUSIONS.: Components of the mTOR pathway are significantly associated with pathological features and survival. Not all RCC tumor types seem to be equally amenable to mTOR targeted therapy. PTEN, pAkt, p27, and pS6 may serve as surrogate parameters for patient selection and predicting prognosis. Patients with a highly activated mTOR pathway should benefit most from this therapy. External validation of our results is recommended. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Self-citationJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Self-citationGrowing roles for the mTOR pathway
Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,560
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Self-citationPKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 923
Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S. C., & Thomas, G. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3112-3124.2004 · Cited by 742
Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., et al. (2002) · Nature Medicine · doi:10.1038/nm762 · Cited by 701
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.111 · Cited by 675
Self-citationBUI, M. H. T., Seligson, D. B., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y., Horvath, S., Leibovich, B. C., Chopra, S., Liao, S. Y., et al. (2003) · PubMed · Cited by 654
Self-citationRini, B. I., Campbell, S. C., & Rathmell, W. K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000219260.60714.c4 · Cited by 379
Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., & Houghton, P. J. (1999) · PubMed · Cited by 310
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8234 · Cited by 303
Akt Signaling and Cancer: Surviving but not Moving On
Toker, A., & Yoeli-Lerner, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0743 · Cited by 295
(2003) · PubMed · Cited by 269
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., O’Toole, T., Kong, S., & Moore, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.lba4 · Cited by 209
Self-citationAbraham, R. T. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80172-6 · Cited by 192
Pantuck, A. J., Zeng, G., Belldegrun, A. S., & Figlin, R. A. (2003) · PubMed · Cited by 182
Self-citationStudies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells
Hosoi, H., Dilling, M. B., Liu, L. N., Danks, M. K., Shikata, T., Sekulic, A., Abraham, R. T., Lawrence, J. C., & Houghton, P. J. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.5.815 · Cited by 172
Loss of tumor suppressor protein PTEN during renal carcinogenesis
Brenner, W., Färber, G., Herget, T., Lehr, H., Hengstler, J. G., & Thüroff, J. W. (2002) · International Journal of Cancer · doi:10.1002/ijc.10303 · Cited by 136
Reduction of Cytosolic p27Kip1 Inhibits Cancer Cell Motility, Survival, and Tumorigenicity
Wu, F. Y., Wang, S. E., Sanders, M. E., Shin, I., Rojo, F., Baselga, J. M., & Arteaga, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3304 · Cited by 130
Epithelial Cell Adhesion Molecule (KSA) Expression
Seligson, D. B., Pantuck, A. J., Liu, X., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1132-03 · Cited by 124
Self-citationOrend, G., Hunter, T. R., & Ruoslahti, E. I. (1998) · Oncogene · doi:10.1038/sj.onc.1201791 · Cited by 124
Velickovic, M., Delahunt, B., McIver, B., & Grebe, S. K. G. (2002) · Modern Pathology · doi:10.1038/modpathol.3880551 · Cited by 94
Goffin, J. R., Baral, S., Tu, D., Nomikos, D., & Seymour, L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0130 · Cited by 91
Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray
Hedberg, Y., Ljungberg, B., Roos, G., & Landberg, G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600922 · Cited by 85
Jiang, Y., Zhao, R. C. H., & Verfaillie, C. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190104497 · Cited by 79
p21 is a Prognostic Marker for Renal Cell Carcinoma: Implications for Novel Therapeutic Approaches
Weiss, R. H., Borowsky, A. D., Seligson, D. B., Lin, P.-Y., Dillard‐Telm, L., Belldegrun, A. S., Figlin, R. A., & Pantuck, A. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.08.073 · Cited by 63
Self-citationHaitel, A., Wiener, H. G., Neudert, B., et al. (2001) · Urology · doi:10.1016/s0090-4295(01)01188-8 · Cited by 49
Cited by
BAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Kapur, P., Peña-Llopis, S., Christie, A., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X.-J., & Brugarolas, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70584-3 · Cited by 471
Common corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
Self-citation
Metadata
- Authors
- Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., O'Toole, T., Gibbons, J., Belldegrun, A. S., & Figlin, R. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-05-18
- Volume
- 109
- Issue
- 11
- Pages
- 2257-2267
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2005942192
- Cited by
- 350
- References
- 41
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.